Xcell Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	1,949	1,934	1,124	1,020	1,966
Other Revenue	-	-	-	0	-
Revenue	1,949	1,934	1,124	1,020	1,966
Revenue Growth (YoY)	0.76%	72.11%	10.18%	-48.12%	264.00%
Cost of Revenue	3,915	3,333	2,987	2,773	2,284
Gross Profit	-1,966	-1,399	-1,863	-1,753	-318.08
Selling, General & Admin	5,463	4,323	3,400	3,219	3,058
Research & Development	2,576	2,728	2,753	2,596	1,832
Amortization of Goodwill & Intangibles	108.25	53.23	53.83	73.48	56.2
Other Operating Expenses	38.81	36.01	71.45	140.21	78.1
Operating Expenses	8,886	7,931	7,076	6,546	5,387
Operating Income	-10,852	-9,330	-8,939	-8,299	-5,705
Interest Expense	-3.43	-4.4	-3.12	-2.89	-179.78
Interest & Investment Income	116.56	201.29	50.84	114.02	41.75
Earnings From Equity Investments	-0.81	-	-	-	-
Currency Exchange Gain (Loss)	-0.57	12.84	2.52	11.57	2.38
Other Non Operating Income (Expenses)	-304.76	-295.6	-257.58	-165.59	-3,186
EBT Excluding Unusual Items	-11,045	-9,416	-9,147	-8,342	-9,026
Gain (Loss) on Sale of Investments	19.02	2.72	-0.87	-	-
Gain (Loss) on Sale of Assets	98.66	-130.13	21	-0.53	-12
Asset Writedown	-	-	-154.12	-	-
Pretax Income	-10,927	-9,543	-9,281	-8,342	-9,038
Net Income	-10,927	-9,543	-9,281	-8,342	-9,038
Net Income to Common	-10,927	-9,543	-9,281	-8,342	-9,038
Shares Outstanding (Basic)	12	10	9	9	8
Shares Outstanding (Diluted)	12	10	9	9	8
Shares Change (YoY)	16.46%	13.11%	1.02%	5.71%	364.87%
EPS (Basic)	-938.00	-954.00	-1049.40	-952.90	-1091.40
EPS (Diluted)	-938.00	-954.00	-1049.40	-953.00	-1091.40
Free Cash Flow	-10,369	-7,379	-7,008	-8,475	-5,952
Free Cash Flow Per Share	-890.07	-737.67	-792.48	-968.02	-718.67
Gross Margin	-100.87%	-72.30%	-165.77%	-171.89%	-16.18%
Operating Margin	-556.79%	-482.33%	-795.37%	-813.59%	-290.14%
Profit Margin	-560.65%	-493.36%	-825.74%	-817.85%	-459.67%
Free Cash Flow Margin	-532.01%	-381.48%	-623.58%	-830.82%	-302.69%
EBITDA	-9,148	-7,677	-7,341	-6,786	-4,686
EBITDA Margin	-	-	-	-	-238.34%
D&A For EBITDA	1,704	1,653	1,598	1,513	1,019
EBIT	-10,852	-9,330	-8,939	-8,299	-5,705
EBIT Margin	-	-	-	-	-290.14%
Advertising Expenses	315.64	154.72	315.24	267.87	279.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.